You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 8,524,746

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,524,746 protect, and when does it expire?

Patent 8,524,746 protects ONGENTYS and is included in one NDA.

This patent has thirty-one patent family members in twenty-three countries.

Summary for Patent: 8,524,746

Patent landscape, scope, and claims:

Title:	Dosage regimen for COMT inhibitors
Abstract:	The invention relates to the use of an oxodiazolyl compound (I) for the preparation of a medicament for the prevention or treatment of central and peripheral nervous system associated disorders, wherein said medicament is administered according to a dosing regimen having a dosing periodicity ranging from about twice a day to about once every other day. ##STR00001##
Inventor(s):	Learmonth; David Alexander (S. Mamede do Coronado, PT), Kiss; Laszlo Erno (S. Mamede do Coronado, PT), Palma; Pedro Nuno Leal (S. Mamede do Coronado, PT), Ferreira; Humberto dos Santos (S. Mamede do Coronado, PT), Silva; Patricio Manuel Vieira Araujo Soares da (S. Mamede do Coronado, PT)
Assignee:	Bial-Portela & Ca., S.A. (S. Mamede do Coronado, PT)
Application Number:	12/524,848
Patent Claim Types: see list of patent claims	Use; Compound;
More… ↓ ⤷ Subscribe

Drugs Protected by US Patent 8,524,746

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Amneal	ONGENTYS	opicapone	CAPSULE;ORAL	212489-001	Apr 24, 2020		RX	Yes	No	8,524,746	⤷ Subscribe				ADJUNCTIVE TREATMENT TO LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSON’S DISEASE EXPERIENCING OFF EPISODES	⤷ Subscribe
Amneal	ONGENTYS	opicapone	CAPSULE;ORAL	212489-002	Apr 24, 2020		RX	Yes	Yes	8,524,746	⤷ Subscribe				ADJUNCTIVE TREATMENT TO LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSON’S DISEASE EXPERIENCING OFF EPISODES	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 8,524,746

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	07002091	Jan 31, 2007

PCT Information
PCT Filed	October 10, 2007	PCT Application Number:	PCT/PT2007/000043
PCT Publication Date:	August 07, 2008	PCT Publication Number:	WO2008/094053

International Family Members for US Patent 8,524,746

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2481410	⤷ Subscribe	C02481410/01	Switzerland	⤷ Subscribe
Argentina	065098	⤷ Subscribe
Argentina	109590	⤷ Subscribe
Australia	2007346018	⤷ Subscribe
Brazil	PI0721213	⤷ Subscribe
Canada	2678391	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.